Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response
Status:
Recruiting
Trial end date:
2027-03-01
Target enrollment:
Participant gender:
Summary
This is a 16-week, open-label study to identify factors that help predict clinical responses
to DMARD therapies for RA (Rheumatoid Arthritis) patients. All patients will receive a
starting dose of DMARD medication(s) which may be adjusted by the investigator as needed. If
a subject becomes intolerant to a DMARD medication the subject will be withdrawn from the
study at the discretion of the investigator. Visits (prior to week 16) where withdrawal is
determined to be necessary will be considered end of study. End of study data (week 16) as
well as study serum will be collected. (Serum only collected on those subjects who have
consented to the addendum Serum and DNA of this study). A portion of the blood collected at
baseline, week 8 and week 16 with the addendum portion of the study is for future research
and will be utilized attempting to look to detect the generation of superoxide radicals. The
radicals have been shown to be associated with inflammation and may correlate with the
progression of RA. If this is true, then treatment with RA should decrease the levels of
these radicals signaling response to treatment.